Evidence map›Paper›PMID 31064628›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2019

QuantiFERON

R L Epstein, M Bhagavathula, L A Saag, S Verma, C K Kan, J Mesick, P Kamineni, L F White, E D Barnett, P Salgame and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

R L EpsteinDepartment of Pediatrics, Section of Pediatric Infectious Diseases, Boston Medical Center, Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts.
M BhagavathulaCentre for Emerging Pathogens, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey.
L A SaagBoston University School of Public Health, Boston, Massachusetts, Department of Epidemiology, Vanderbilt University, Nashville, Tennessee.
S VermaCentre for Emerging Pathogens, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey.
C K KanBoston University School of Public Health, Boston, Massachusetts, Boston University School of Medicine, Boston, Massachusetts.
J MesickBoston University School of Public Health, Boston, Massachusetts, College of Osteopathic Medicine, Touro University California, Vallejo, California.
P KamineniBoston University School of Public Health, Boston, Massachusetts.
L F WhiteDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
E D BarnettDepartment of Pediatrics, Section of Pediatric Infectious Diseases, Boston Medical Center.
P SalgameCentre for Emerging Pathogens, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey.
N S HochbergDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, Boston University School of Public Health, Boston, Massachusetts.
Boston University · USBoston Medical Center · USRutgers New Jersey Medical SchoolRutgers, The State University of New Jersey · USTouro University California · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
BU Clinical HIV/AIDS Research Training Program (BU-CHART)T32AI052074 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Benjamin P. Linas · 2003 to 2026
$6.7M
NRSA Training CoreTL1TR002244 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2017 to 2026
$4.6M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)TL1TR000447 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$1.2M
NCATS NIH HHS TL1 TR000447NCATS NIH HHS TL1 TR002244NCATS NIH HHS UL1 TR001430NIAID NIH HHS P30 AI042853NIAID NIH HHS T32 AI052074
6 · The paper itself

Abstract

<sec id="st1"> <title>SETTING</title> Accurate testing and treatment for latent tuberculous infection is necessary for tuberculosis elimination. Certain parasite infections are associated with increased tuberculin skin test positivity; species-specific effects on QuantiFERON

Indexed as

Emigrants and ImmigrantsAdolescentAdultAgedAged, 80 and overBostonChildChild, PreschoolCytokinesFemaleHumansInterferon-gamma Release TestsLatent TuberculosisMaleMass ScreeningMiddle AgedCytokines

Identifiers

PMID31064628
PMCPMC6690781
OpenAlexW2944538618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.